|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/28/20 Anavex Life Sciences Corp. 10-K 9/30/20 44:3.6M Electro Filings LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 794K
2: EX-21.1 Subsidiaries List HTML 13K
3: EX-23.1 Consent of Expert or Counsel HTML 13K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 18K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 18K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 14K
13: R1 Cover HTML 77K
14: R2 Consolidated Balance Sheets HTML 55K
15: R3 Consolidated Balance Sheets (Parenthetical) HTML 26K
16: R4 Consolidated Statements of Operations HTML 61K
17: R5 Consolidated Statements of Cash Flows HTML 58K
18: R6 Consolidated Statement of Changes in Stockholders' HTML 60K
Equity
19: R7 Business Description and Basis of Presentation HTML 25K
20: R8 Summary of Significant Accounting Policies HTML 57K
21: R9 Other Income HTML 22K
22: R10 Equity Offering Agreements HTML 39K
23: R11 Commitments HTML 84K
24: R12 Income Taxes HTML 44K
25: R13 Summary of Significant Accounting Policies HTML 94K
(Policies)
26: R14 Commitments (Tables) HTML 74K
27: R15 Income Taxes (Tables) HTML 37K
28: R16 Summary of Significant Accounting Policies HTML 18K
(Details Narrative)
29: R17 Other Income (Details Narrative) HTML 26K
30: R18 Equity Offering Agreements (Details Narrative) HTML 55K
31: R19 Commitments (Details) HTML 33K
32: R20 Commitments (Details 1) HTML 26K
33: R21 Commitments (Details 2) HTML 47K
34: R22 Commitments (Details 3) HTML 21K
35: R23 Commitments (Details 4) HTML 23K
36: R24 Commitments (Details Narrative) HTML 38K
37: R25 Income Taxes (Details) HTML 22K
38: R26 Income Taxes (Details 1) HTML 31K
39: R27 Income Taxes (Details 2) HTML 37K
40: R28 Income Taxes (Details Narrative) HTML 26K
42: XML IDEA XML File -- Filing Summary XML 69K
12: XML XBRL Instance -- e2298_10k_htm XML 537K
41: EXCEL IDEA Workbook of Financial Reports XLSX 53K
8: EX-101.CAL XBRL Calculations -- avxl-20200930_cal XML 77K
9: EX-101.DEF XBRL Definitions -- avxl-20200930_def XML 200K
10: EX-101.LAB XBRL Labels -- avxl-20200930_lab XML 561K
11: EX-101.PRE XBRL Presentations -- avxl-20200930_pre XML 398K
7: EX-101.SCH XBRL Schema -- avxl-20200930 XSD 85K
43: JSON XBRL Instance as JSON Data -- MetaLinks 181± 247K
44: ZIP XBRL Zipped Folder -- 0001731122-20-001338-xbrl Zip 253K
Exhibit 31.1
CERTIFICATION
I, Christopher Missling, certify that:
| 1. | I have reviewed this Annual Report on Form 10-K of Anavex Life Sciences Corp.; | |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and | |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): | |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. | |
| Date: December 28, 2020 | |
| /s/ Christopher Missling | |
| Christopher Missling, PhD | |
| Chief Executive Officer, President, Secretary (Principal Executive Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 12/28/20 | 8-K | ||
| For Period end: | 9/30/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/16/21 Anavex Life Sciences Corp. 424B5 1:299K Electro Filings LLC/FA |